LABORATORIO ELEA PHOENIX S.A.
🇦🇷Argentina
- Country
- 🇦🇷Argentina
- Ownership
- -
- Established
- 2010-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://ctbe.cnpem.br/
Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2015-10-22
- Lead Sponsor
- Laboratorio Elea Phoenix S.A.
- Target Recruit Count
- 24
- Registration Number
- NCT02583464
- Locations
- 🇦🇷
Laboratorio Elea SACIFyA, Capital Federal, Buenos Aires, Argentina
Recurrent and Nonrecurrent Condyloma Treatment
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Laboratorio Elea Phoenix S.A.
- Target Recruit Count
- 132
- Registration Number
- NCT01639638
- Locations
- 🇦🇷
Laboratorio Elea SACIFyA, Capital Federal, Buenos Aires, Argentina
Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Laboratorio Elea Phoenix S.A.
- Target Recruit Count
- 18
- Registration Number
- NCT01639625
- Locations
- 🇦🇷
Instituto de Oncologia Angel H. Roffo, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Laboratorio Elea Phoenix S.A.
- Target Recruit Count
- 30
- Registration Number
- NCT01623206
- Locations
- 🇦🇷
Hospital de Gastroenterologia ¨B.Udaondo¨, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
🇦🇷Instituto de OncologÃa "Alexander Fleming", Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Perioperative Use of Desmopressin (DDAVP) in Breast Cancer
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2015-08-28
- Lead Sponsor
- Laboratorio Elea Phoenix S.A.
- Target Recruit Count
- 21
- Registration Number
- NCT01606072
- Locations
- 🇦🇷
Hospital Interzonal General De Agudos EvaPeron, Buenos Aires, Argentina
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- Laboratorio Elea Phoenix S.A.
- Target Recruit Count
- 15
- Registration Number
- NCT01598454
- Locations
- 🇦🇷
Prof. Dr. J. P. Garrahan National Children's Hospital, Buenos Aires, Argentina
Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Laboratorio Elea Phoenix S.A.
- Target Recruit Count
- 7
- Registration Number
- NCT01240447
- Locations
- 🇦🇷
Instituto de OncologÃa "Angel H. Roffo", Buenos Aires, Argentina
© Copyright 2024. All Rights Reserved by MedPath